1987; 317 : 1237-1245 In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels of non-HDL cholesterol with gemfibrozil in reducing the risk of coronary heart disease in 4081 asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to Methods: We conducted a double-blind trial comparing gemfibrozil (1200 mg per day) with placebo in 2531 men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1
1%) in the placebo group; including the 3
2 mM; 200 mg/dL), 135 had NIDDM at entry
Clinical results with gemfibrozil and background to the Helsinki Heart Study
5 year follow-up period since the trial was completed, cumulative mortality from any cause was 101 (4
The Helsinki Heart Study is a coronary primary prevention trial in a group of middle aged men with lipid abnormalities
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia
9%) in the gemfibrozil group and 83 (4
9%) in the gemfibrozil group and 83 (4
2%) in the gemfibrozil group and 43 (2
, 1988)
Its aim is to investigate the effects on the incidence of coronary heart disease of simultaneously lowering serum total and low density lipoprotein (LDL)-cholesterol and elevating high density lipoprotein (HDL)-cholesterol Synopsis Gemfibrozil improves lipid and apolipoprotein profiles, particularly very low density lipoprotein (VLDL) triglyceride and high density lipoprotein (HDL) cholesterol levels, in patients with dyslipidaemia when administered at a total daily dose of 900 or 1200mg
In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels of non-HDL cholesterol with gemfibrozil in reducing the risk of coronary heart disease in 4081 asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non-HDL cholesterol greater than or equal to During the five year primary prevention component of the Helsinki Heart Study, mortality from any cause was 44 (2
1%) in the placebo group; including the 3
2%) in the LOPID group and 43 (2
9%) in the gemfibrozil group and 83 (4
1016/0002-9149(83)90656-2 Corpus ID: 31638171; Clinical results with gemfibrozil and background to the Helsinki Heart Study
5 year follow-up period since the trial was completed, cumulative mortality from any cause was 101 (4
1056/NEJM198711123172001
The Helsinki Heart Study tested the effect of modifying plasma low density lipoprotein (LDL)- and high density lipoprotein (HDL)-cholesterol on the primary prevention of
In summary, VA-HIT, which was conducted with the fibric acid derivative gemfibrozil, is the first lipid intervention trial to show that raising HDL-C concentrations
The Helsinki Heart Study tested the effect of modifying plasma low density lipoprotein (LDL)- and high density lipoprotein (HDL)-cholesterol on the primary
N Engl J Med 317: 1237–1245
Gemfibrozil substantially increases plasma concentrations of high-density lipoprotein (HDL)-cholesterol (Goodman Gilman et al
The Helsinki Heart Study (HHS) is a randomized double-blinded trial that assessed the primary cardiovascular preventive effect of elevation in HDL and decrease in non-HDL cholesterol with gemfibrozil
Total mortality was equal during the original 5 years, but higher in the gemfibrozil group post-trial, leading to an 8
Design: All participants of the Helsinki Heart Study, a controlled 5-year CHD primary prevention trial with gemfibrozil and placebo, were offered gemfibrozil treatment and biannual follow-up for 3
1%) in the placebo group; including the 3
Its aim is to investigate the effects on the incidence of coronary heart disease of simultaneously lowering serum total and low density lipoprotein (LDL)-cholesterol and elevating high density lipoprotein (HDL)-cholesterol
9 Furthermore, between 2007 and 2016 DOI: 10
1987; 317(20):1237-45 (ISSN: 0028-4793) Frick MIT, Elo O, Haapa K et al
, the Helsinki Heart Study), gemfibrozil has been shown to reduce coronary heart disease (Grundy, 1988; Manninen et al
The Helsinki Heart Study is a coronary primary prevention trial in a group of middle aged men with lipid abnormalities
In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels of non-HDL cholesterol with gemfibrozil in reducing the risk of coronary heart disease in 4081 asymptomatic middle-aged men (40 to 55 years of age) with primary dyslipidemia (non
To control the bias caused by poor medication compliance in the Helsinki Heart Study three methods were used to measure medication compliance during the total 5 years follow up time: continuous capsule counting, semi-annual urine gemfibrozil analysis and a new method, the digoxin marker at the end of the third and fifth study years
20 VA‐HIT 11 compared the effects of gemfibrozil with placebo During the five year primary prevention component of the Helsinki Heart Study, mortality from any cause was 44 (2
1%) in the Averaged over the 5-year trial period, gemfibrozil induced mean decreases of 11% in LDL-cholesterol and 35% in triglycerides and a mean increase of 11% in HDL-cholesterol compared with placebo